Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional in Vivo Response to BMN 673

INTRODUCTION: BMN 673 is a potent inhibitor of poly-ADP ribose polymerase (PARP) that is in clinical testing with a primary focus on BRCA-mutated cancers. BMN 673 is active both through inhibiting PARP catalytic activity and by tightly trapping PARP to DNA at sites of single strand breaks. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Smith, Malcolm A., Hampton, Oliver A., Reynolds, C. Patrick, Kang, Min H., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Carol, Hernan, Keir, Stephen T., Wu, Jianrong, Kurmasheva, Raushan T., Wheeler, David A., Houghton, Peter J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4456187/
https://ncbi.nlm.nih.gov/pubmed/25263539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25201
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados